GET DAILY SIGNALSSAB Biotherapeutics (SABS) Narrows Q3 Loss as SAFEGUARD Trial Advances
Key Takeaways
- SAB Biotherapeutics posted a third-quarter 2026 net loss of $22.3 million, or $0.24 per share, narrower than the consensus estimate of a $0.27 loss.
- The clinical-stage biopharmaceutical company reported no revenue for the quarter, consistent with its pre-commercial status.
- Research and development (R&D) expenses climbed to $18.1 million from $9.0 million a year earlier, driven by the registrational SAFEGUARD study of SAB-142.
- Cash, cash equivalents, and investment securities totaled $205.3 million, which management says supports an operational runway through 2028.
- The adult and adolescent cohorts of the SAFEGUARD trial are fully enrolled, and the U.S. Food and Drug Administration (FDA) granted Fast Track designation to SAB-142.
- For more on SABS's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
- Explore Trending AI Robots to see AI-driven trading strategies in action.
Earnings Context and Why It Matters
SAB Biotherapeutics is developing SAB-142, a fully human anti-thymocyte globulin (hATG) immunotherapy intended to treat Stage 3 type 1 diabetes (T1D). Because the company has no approved products, its quarterly earnings are driven less by top-line revenue and more by clinical execution and cash management. Investors watch spending closely, but the real catalyst is the progress of the ~159-patient SAFEGUARD registrational study, with topline data expected in the second half of 2027. Against that backdrop, this report matters chiefly for what it reveals about enrollment, safety, and the company's financial runway to reach its next major data milestones. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, SAB Biotherapeutics reported a net loss of $22.3 million, or $0.24 per share, beating the consensus estimate of a $0.27 loss. The company reported no revenue for the period, which is typical for a pre-commercial biotech.
Operating expenses rose as the SAB-142 program advanced. R&D expenses increased to $18.1 million from $9.0 million in the prior-year quarter, while general and administrative (G&A) expenses grew to $7.8 million from $3.7 million. A meaningful portion of both increases reflected non-cash stock-based compensation of roughly $7.5 million across the two categories, compared with about $0.8 million a year earlier.
The year-over-year comparison is distorted by a non-operating swing. In the prior-year quarter, the company reported net income of $45.4 million, driven largely by $58.1 million in other income tied to changes in the fair value of warrant liabilities. Stripping out that effect, the underlying cost trend is clearly higher, consistent with a company running a large registrational trial across more than 60 sites. Management reaffirmed guidance, leaving its cash runway through 2028 unchanged.
Market Reaction and Investor Sentiment
Heading into the report, investor sentiment had improved modestly, and the narrower-than-expected loss offered a supportive, if secondary, signal. For a clinical-stage company, however, the EPS beat matters less than program execution. The market's focus has centered on SAFEGUARD enrollment progress, the pediatric step-down approval to ages 5–11 with no new safety signals, and the FDA's Fast Track designation for SAB-142. These milestones reinforce the credibility of the development timeline, though rising cash burn and the distance to the second-half 2027 topline readout remain key risk factors that could temper enthusiasm.
Forward Outlook and Key Factors to Monitor
Looking ahead, the primary catalysts are clinical rather than financial. Management reaffirmed that overall SAFEGUARD enrollment remains on track for completion in the fourth quarter of 2026, with topline data expected in the second half of 2027. The primary endpoint is preservation of beta cell function as measured by C-peptide, a marker of insulin production, alongside glycemic control metrics including HbA1c (a measure of average blood sugar) and continuous glucose monitoring data.
Investors will also watch the investigator-led PRISE-hATG Phase 3 trial, funded by Breakthrough T1D, which could extend the potential label to patients up to two years post-diagnosis. The first patient dosing was expected in the fourth quarter of 2026. The FDA's Fast Track designation for SAB-142 brings more frequent agency interaction and eligibility for rolling submission of a Biologics License Application (BLA), the formal request for marketing approval.
On the financial side, the key variable is spending discipline. Cash fell to $205.3 million from $217.6 million at the end of the prior quarter, even after $13.4 million in warrant-exercise proceeds. Management has said PRISE-related costs are already embedded in its burn guidance and reaffirmed runway through 2028. Investors should monitor the pace of quarterly operating losses against that runway, along with any updated disclosure on safety, redosing durability, and differentiation versus Tzield, the competing therapy now marketed for Stage 3 T1D. From what I see, this is important because it highlights the execution risks ahead.
AI Tools in My Research Process
I often turn to Tickeron’s AI Screener when evaluating clinical-stage names like SABS. It lets me quickly filter for technical patterns, fundamentals, and AI signals across the biotech sector, helping me compare cash runway and trial progress against peers without spending hours on manual screens. This kind of tool has become a regular part of how I prepare for earnings like these.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SABS's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for SABS turned positive on October 21, 2026. Looking at past instances where SABS's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SABS's RSI Indicator exited the oversold zone, 23 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on SABS as a result. In 73 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
Following a +4.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where SABS advanced for three days, in 167 of 211 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
SABS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 43 cases where SABS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
SABS moved below its 50-day moving average on November 03, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SABS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SABS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. SABS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.284) is normal, around the industry mean (3.482). P/E Ratio (2.424) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SABS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement